Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imsidolimab - AnaptysBio

Next Previous
X
Search
Drug Profile

Imsidolimab - AnaptysBio

Alternative Names: ANB 019

Latest Information Update: 29 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Generalised pustular psoriasis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pustular psoriasis

Highest Development Phases

  • Phase III Generalised pustular psoriasis
  • Phase II Acneiform eruptions; Ichthyosis
  • No development reported Palmoplantar pustulosis
  • Discontinued Acne vulgaris; Hidradenitis suppurativa

Most Recent Events

  • 17 Jul 2024 AnaptysBio terminates phase-III GEMINI-2 trial in Generalised pustular psoriasis in USA, Australia, France, Georgia, Germany, South Korea, Malaysia, Morocco, Poland, Romania, Spain, Taiwan, Thailand, Tunisia and Turkey (IV) due to conclusion of the trial with all trial participants having been treated with imsidolimab for approximately six months and the furthest patient having been treated through 92 weeks (NCT05366855)
  • 09 May 2024 Efficacy and adverse events data from a phase III GEMINI-2 trial in Generalized pustular psoriasis released by AnaptysBio
  • 12 Apr 2024 AnaptysBio has patent protection for imsidolimab in various countries, as of December 2023 (AnaptysBio, Form 10-K)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top